Avalo Therapeutics, Inc.
NASDAQ:AVTX
4.96 (USD) • At close July 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.441 | 1.924 | 18.051 | 5.398 | 6.699 | 6.75 | 18.327 | 27.813 | 1.153 | 0 | 0 | 0 | 0.083 |
| Cost of Revenue
| -0.366 | 1.284 | 3.434 | 1.491 | 0.3 | 11.629 | 7.478 | 0.636 | 8.239 | 0.024 | 9.5 | 0 | 8.477 |
| Gross Profit
| 0.807 | 0.64 | 14.617 | 3.907 | 6.399 | -4.879 | 10.849 | 27.177 | -7.086 | -0.024 | -9.5 | 0 | -8.394 |
| Gross Profit Ratio
| 1.83 | 0.333 | 0.81 | 0.724 | 0.955 | -0.723 | 0.592 | 0.977 | -6.146 | 0 | 0 | 0 | -101.424 |
| Reseach & Development Expenses
| 52.078 | 13.784 | 31.308 | 59.835 | 32.193 | 11.764 | 5.787 | 4.373 | 10.15 | 6.587 | 12.241 | 8.914 | 8.477 |
| General & Administrative Expenses
| 16.452 | 10.267 | 20.635 | 21.832 | 17.418 | 10.124 | 10.677 | 7.942 | 7.083 | 4.423 | 4.875 | 4.02 | 2.097 |
| Selling & Marketing Expenses
| 0.789 | 0.033 | 0.076 | 2.826 | 2.341 | 1.484 | 8.522 | 0.973 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.241 | 10.3 | 20.711 | 24.658 | 19.759 | 11.608 | 19.199 | 8.915 | 7.083 | 4.423 | 4.875 | 4.02 | 2.097 |
| Other Expenses
| 0 | 3.907 | 0.038 | 1.548 | 1.741 | 1.339 | 0.014 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 69.319 | 27.991 | 52.057 | 86.041 | 53.693 | 24.711 | 29.518 | 13.288 | 17.233 | 11.01 | 17.116 | 12.934 | 2.097 |
| Operating Income
| -68.512 | -27.351 | -37.44 | -82.134 | -26.953 | -17.394 | -39.314 | 13.89 | -16.08 | -11.01 | -17.116 | -12.934 | -10.491 |
| Operating Income Ratio
| -155.356 | -14.216 | -2.074 | -15.216 | -4.023 | -2.577 | -2.145 | 0.499 | -13.946 | 0 | 0 | 0 | -126.764 |
| Total Other Income Expenses Net
| 33.497 | -4.179 | -4.19 | -2.411 | 5.666 | 12.26 | 0.055 | -0.054 | -0.392 | 0.52 | 1.06 | -0.111 | 0.001 |
| Income Before Tax
| -35.015 | -31.53 | -41.63 | -84.545 | -67.177 | -15.991 | -40.087 | 13.836 | -16.471 | -10.49 | -16.056 | -13.045 | -10.49 |
| Income Before Tax Ratio
| -79.399 | -16.388 | -2.306 | -15.662 | -10.028 | -2.369 | -2.187 | 0.497 | -14.285 | 0 | 0 | 0 | -126.747 |
| Income Tax Expense
| 0.114 | 0.014 | 0.028 | -0.196 | -2.793 | 0.28 | -0.034 | 1.967 | 0.364 | -0.544 | -1.06 | 0.111 | 0 |
| Net Income
| -35.129 | -31.544 | -41.658 | -84.349 | -64.384 | -16.271 | -40.053 | 11.87 | -16.471 | -10.49 | -16.056 | -13.045 | -10.49 |
| Net Income Ratio
| -79.658 | -16.395 | -2.308 | -15.626 | -9.611 | -2.411 | -2.185 | 0.427 | -14.285 | 0 | 0 | 0 | -126.747 |
| EPS
| -4.32 | -113.58 | -1,062.65 | -2,330.66 | -2,523.77 | -819.74 | -3,317.28 | 1,856.88 | -21.93 | -16.21 | -41.61 | -43.12 | -199.77 |
| EPS Diluted
| -3.26 | -113.58 | -1,062.65 | -2,330.66 | -2,523.77 | -819.74 | -3,317.28 | 1,822.74 | -21.93 | -16.21 | -41.61 | -43.12 | -199.77 |
| EBITDA
| -68.343 | -23.286 | -37.294 | -80.497 | -45.451 | -17.361 | -13.072 | 14.345 | -16.053 | -10.458 | -17.087 | -12.914 | -10.476 |
| EBITDA Ratio
| -154.973 | -12.103 | -2.066 | -14.912 | -6.785 | -2.572 | -0.713 | 0.516 | -13.923 | 0 | 0 | 0 | -126.582 |